Biocon Biologics invests ₹250 Crore in Bengaluru facility expansion.

Biocon Biologics India Ltd. is undertaking a significant expansion of its bio-pharmaceutical project at Hebbagodi, Bengaluru, Karnataka. The project, valued at ₹250 crores, aims to bolster the company's production capacity to 371.75 tons per annum (TPA) and enhance its infrastructure for treating effluents, with a daily capacity of 250 kiloliters.

This expansion underscores Biocon Biologics' commitment to meeting the growing demand for bio-pharmaceutical products both domestically and internationally. By increasing its production capabilities, the company is poised to strengthen its position in the competitive pharmaceutical industry and support the global healthcare system.

The project will also contribute to the local economy by creating job opportunities and fostering technological advancements in the bio-pharmaceutical sector. The increased production capacity is expected to cater to a broader range of therapeutic needs, addressing critical health challenges with innovative solutions.

Moreover, the enhancement in effluent treatment facilities aligns with Biocon's sustainability goals, ensuring that the environmental impact of its operations is minimized. This focus on eco-friendly practices highlights the company's dedication to responsible manufacturing and environmental stewardship.

In summary, Biocon Biologics' expansion at Hebbagodi marks a pivotal step in its growth trajectory, enhancing its production capabilities and environmental sustainability, thereby reaffirming its leadership in the bio-pharmaceutical industry.

News by Rahul Yelligetti